Business Context and Reporting Period
Company: Achieve Life Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 22, 2022
Reporting Period: Event date November 22, 2022; Financial data referenced as of September 30, 2022.
Key Financial Metrics
Stockholders' Equity: $1.0 million (as of September 30, 2022, per Form 10-Q).
Listing Requirement: Minimum stockholders' equity of $2.5 million required by Nasdaq Listing Rule 5550(b)(1).
Other Metrics: The filing does not provide specific values for revenue, profit, cash flow, margins, or debt. The company also failed to meet alternative compliance standards regarding market value of listed securities or net income from continuing operations.
Material Changes
The Company received notification from Nasdaq on November 22, 2022, that it is not in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. This non-compliance is based on the equity balance reported in the most recent quarterly filing.
Outlook, Management Commentary, and Risks
- Compliance Timeline: Nasdaq has granted the Company 45 calendar days (until January 6, 2023) to submit a plan to regain compliance.
- Extension Possibility: If a plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from November 22, 2022.
- Delisting Risk: Failure to submit an acceptable plan or regain compliance within the required timeframe could result in a notice of delisting.
- Management Plan: The Company expects to submit a plan detailing the impact of a recent private offering of securities, which management believes will be sufficient to restore compliance with the $2.5 million equity requirement.
Investor Verification Checklist
- Verify the final terms and closing date of the recent private offering of securities mentioned by management.
- Confirm the updated stockholders' equity balance post-offering to ensure it meets the $2.5 million threshold.
- Monitor the submission and acceptance status of the compliance plan by the January 6, 2023 deadline.
- Review the Form 10-Q for the quarter ended September 30, 2022, for detailed financial context regarding the equity shortfall.